<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434369</url>
  </required_header>
  <id_info>
    <org_study_id>510-08</org_study_id>
    <nct_id>NCT00434369</nct_id>
  </id_info>
  <brief_title>5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients</brief_title>
  <official_title>A Multi-Center, Open-Label, Single-Arm Phase II Trial Assessing the Efficacy and Safety of Weekly Bolus Infusions of 5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Advanced Breast Cancer Patients Who Failed Anthracycline and Taxane Chemotherapy Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mast Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      A multi-center, open-label, single-arm Phase II trial assessing the efficacy and safety of&#xD;
      weekly bolus infusions of 5-fluorouracil combined with CoFactor (5-10&#xD;
      methylenetetrahydrofolate) in advanced breast cancer patients who failed anthracycline and&#xD;
      taxane chemotherapy regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CoFactor (ANX-510)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Women with a histologically/cytologically proven diagnosis of advanced adenocarcinoma&#xD;
             of the breast.&#xD;
&#xD;
          -  Measurable disease. At least one unidimensionally measurable non-bony lesion with a&#xD;
             diameter &gt;=10 mm using spiral CT scans (use of spiral CT must be documented in medical&#xD;
             records and used consistently throughout the study) or &gt;= 20 mm using conventional CT&#xD;
             or MRI scans outside the irradiated area according to RECIST criteria.&#xD;
&#xD;
          -  Patients having failed both prior anthracycline and taxane derivative chemotherapy&#xD;
             regimens. Anthrocycline and Taxane failure definitions as defined in the protocol.&#xD;
&#xD;
          -  No more than two prior chemotherapy regimens for advanced disease.&#xD;
&#xD;
          -  Performance status (ECOG) &lt;= 2 or Karnofsky &gt;= 70&#xD;
&#xD;
          -  Age &gt;= 18 years.&#xD;
&#xD;
          -  Life expectancy &gt;= 12 weeks.&#xD;
&#xD;
          -  Adequate organ function as shown by the following:&#xD;
&#xD;
               1. WBCs &gt;= 3.0 x 109/L, absolute neutrophil count (ANC)&gt;= 1.5 x 109/L, platelets &gt;=&#xD;
                  100 x 109/L, hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
               2. Bilirubin &lt;= 1.25 x the upper limit of normal (ULN),aspartate&#xD;
                  aminotransferase(AST or alanine aminotransferase(ALT),= 3 x ULN (or &lt;= 5 x ULN in&#xD;
                  case of liver metastases)&#xD;
&#xD;
               3. Serum calcium within normal limits&#xD;
&#xD;
               4. Serum albumin within the normal range for the study site&#xD;
&#xD;
               5. Creatinine clearance &gt;= 60 mL/min (Cockroft and Gault)&#xD;
&#xD;
               6. Left ventricular ejection fraction (LVEF) within normal limits as shown by&#xD;
                  echocardiography or scintigraphy (multiple-gated acquisition scan).&#xD;
&#xD;
          -  Patients of childbearing potential must be using medically acceptable contraception&#xD;
             for 4 weeks before start of study treatment and 4 months after study treatment&#xD;
             completion. Patients of childbearing potential must have a negative pregnancy test&#xD;
             result within 7 days prior to study treatment initiation.&#xD;
&#xD;
          -  Patients with parenchymal brain metastases must be either adequately controlled&#xD;
             following resection or completed appropriate radiation therapy and be receiving a&#xD;
             stable corticosteroid dose prior to study entry. Patients with leptomeningeal&#xD;
             involvement should not be included in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Her2/neu positive tumor (2+ or 3+).&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Systemic cytotoxic anti-cancer therapy within &lt;=4 weeks of study entry, or 6 weeks if&#xD;
             the systemic therapy contains a nitrosourea or mitomycin C. Hormonal anti-cancer&#xD;
             treatment must be ongoing, or must have been discontinued &gt;3 months before study&#xD;
             entry.&#xD;
&#xD;
          -  Prior 5-FU- and/or capecitabine-based palliative chemotherapy.&#xD;
&#xD;
          -  Extensive prior radiotherapy affecting more than 30% of bone marrow reserves, or bone&#xD;
             marrow / stem cell transplantation.&#xD;
&#xD;
          -  Participation in clinical studies of non-approved experimental agents or procedures&#xD;
             within &lt;=4 weeks of study entry.&#xD;
&#xD;
          -  History of other malignancy, unless cured and the patient has been disease-free for&#xD;
             &gt;=2 years. Patients with a history of cervical carcinoma in situ or cured stage I&#xD;
             cervical cancer, or of epidermal or basal cell skin cancer, may be eligible for&#xD;
             enrollment after discussion with the sponsor.&#xD;
&#xD;
          -  Previous unexpected reaction to fluoropyrimidines, with or without documented&#xD;
             deficiency of dihydropyrimidine dehydrogenase, or known hypersensitivity to 5-FU.&#xD;
&#xD;
          -  Psychologic, familial, sociologic or geographic conditions which do not permit&#xD;
             compliance with the study protocol and/or study.&#xD;
&#xD;
          -  Significant cardiac disease, including symptomatic ventricular arrhythmia, congestive&#xD;
             heart failure, myocardial infarction within 12 months before study entry.&#xD;
&#xD;
          -  Concomitant treatment with any experimental drug or anti-cancer drug, except hormone&#xD;
             therapy or bisphosphonates.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Site in</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site</name>
      <address>
        <city>Acapulco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site in</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>February 7, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2007</study_first_posted>
  <last_update_submitted>April 18, 2008</last_update_submitted>
  <last_update_submitted_qc>April 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

